Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atsushi Kuga

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Neuropsychiatric Disease and Treatment|October 17, 2017
Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational studyEiji Harada, Yoichi Satoi, Atsushi Kuga, et al.
Neuropsychiatric Disease and Treatment|August 24, 2017
An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of lifeAtsushi Kuga, Toshinaga Tsuji, Shinji Hayashi, et al.
Neuropsychiatric Disease and Treatment|August 24, 2017
An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysisAtsushi Kuga, Toshinaga Tsuji, Shinji Hayashi, et al.
The Journal of Biological Chemistry|January 25, 2012
Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycanAtsushi Kuga, Motoi Kanagawa, Atsushi Sudo, et al.
Cell Reports|March 1, 2016
Identification of a Post-translational Modification with Ribitol-Phosphate and Its Defect in Muscular DystrophyMotoi Kanagawa, Kazuhiro Kobayashi, Michiko Tajiri, et al.
Immunological Medicine|February 13, 2026
Pharmacokinetics, safety and tolerability, and efficacy of hyaluronidase-facilitated subcutaneous immunoglobulin 10% (HyQvia<sup>®</sup>) in Japanese patients with primary immunodeficiency diseasesHirokazu Kanegane, Masataka Ishimura, Eisuke Suganuma, et al.
Nature|October 8, 2011
Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophyMariko Taniguchi-Ikeda, Kazuhiro Kobayashi, Motoi Kanagawa, et al.
Immunotherapy Advances|March 21, 2024
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label studyHirokazu Kanegane, Akifumi Endo, Satoshi Okada, et al.
Human Molecular Genetics|April 9, 2013
Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expressionMotoi Kanagawa, Chih-Chieh Yu, Chiyomi Ito, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Neuropsychiatric Disease and Treatment|October 17, 2017
Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational studyEiji Harada, Yoichi Satoi, Atsushi Kuga, et al.
Neuropsychiatric Disease and Treatment|August 24, 2017
An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of lifeAtsushi Kuga, Toshinaga Tsuji, Shinji Hayashi, et al.
Neuropsychiatric Disease and Treatment|August 24, 2017
An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysisAtsushi Kuga, Toshinaga Tsuji, Shinji Hayashi, et al.
The Journal of Biological Chemistry|January 25, 2012
Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycanAtsushi Kuga, Motoi Kanagawa, Atsushi Sudo, et al.
Cell Reports|March 1, 2016
Identification of a Post-translational Modification with Ribitol-Phosphate and Its Defect in Muscular DystrophyMotoi Kanagawa, Kazuhiro Kobayashi, Michiko Tajiri, et al.
Immunological Medicine|February 13, 2026
Pharmacokinetics, safety and tolerability, and efficacy of hyaluronidase-facilitated subcutaneous immunoglobulin 10% (HyQvia<sup>®</sup>) in Japanese patients with primary immunodeficiency diseasesHirokazu Kanegane, Masataka Ishimura, Eisuke Suganuma, et al.
Nature|October 8, 2011
Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophyMariko Taniguchi-Ikeda, Kazuhiro Kobayashi, Motoi Kanagawa, et al.
Immunotherapy Advances|March 21, 2024
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label studyHirokazu Kanegane, Akifumi Endo, Satoshi Okada, et al.
Human Molecular Genetics|April 9, 2013
Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expressionMotoi Kanagawa, Chih-Chieh Yu, Chiyomi Ito, et al.
Pageof 2